Aeluma Q3 Revenue Flat, Guidance Narrowed Amid AI Photonics Interest

What happened

Aeluma's fiscal Q3 revenue remained flat at $1.2 million, with management attributing increased customer interest to AI data center photonics supply constraints, but the full-year revenue outlook was narrowed to $4.2–4.6 million due to contract start delays. The DeepValue report underscores that revenue is still 'primarily from R&D contracts' and government award cadence has decelerated sharply, while the $50 million ATM overhangs the stock as a potential dilution risk. Despite the bullish AI tailwind narrative, the filings show no disclosed production qualification or volume shipments from key partnerships with Tower Semiconductor or Sumitomo Chemical. The stock has rallied to $31.50, pricing in a commercial inflection that the report's base and bear scenarios (combined 85% probability) suggest is unlikely within the next 1–2 quarters. The next 90-day checkpoints—specifically a revenue mix shift away from R&D and avoidance of ATM sales before production milestones—will be critical to sustaining the current valuation.

Implication

The current $384 million market cap embeds a rapid shift to commercial revenue that the latest filing does not support. Investors should demand a clear revenue mix shift in the next quarterly report, as the $50 million ATM creates an acute dilution risk if used before production qualification is disclosed. Government awards have weakened, and FY guidance narrowed, making the next few quarters a credibility test for management's AI datacom narrative. The most probable base and bear scenarios (85% combined) point to a value range of $18–$27, far below today's $31.50. If the stock does not show tangible commercial progress by August 2026, the risk-reward becomes skewed to the downside, with active ATM usage accelerating the decline.

Thesis delta

The news of flat revenue and narrowed guidance reinforces the DeepValue report's caution: the commercial inflection thesis remains unproven. The AI data center interest is a tailwind but has not translated into revenue, while delays and flat results increase the likelihood of ATM dilution. Investors should lower conviction until the company demonstrates a shift from R&D to product revenue and avoids tapping the ATM before production milestones.